Led by $255m venture financing of InSilico Medicine, North America’s medical devices industry saw a drop of 5.08% in artificial intelligence deal activity during Q2 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 28 artificial intelligence deals worth $1.2bn were announced for the region during Q2 2021, against the last four-quarter average of 29.50 deals.
Of all the deal types, venture financing saw most activity in Q2 2021 with 21 deals, representing a 75% share for the region.
In second place was M&A with four deals, followed by private equity deals with three transactions, respectively capturing a 14.3% and 10.7% share of the overall artificial intelligence deal activity for the quarter.
In terms of value of artificial intelligence deals, venture financing was the leading category in North America’s medical devices industry with $986.43m, while private equity and M&A deals totalled $135.5m and $49.65m, respectively.
North America medical devices industry artificial intelligence deals in Q2 2021: Top deals
The top five medical devices artificial intelligence deals accounted for a 60.2% share of the overall value during Q2 2021.
The combined value of the top five artificial intelligence deals stood at $705m, against the overall value of $1.2bn recorded for the quarter.
The top five medical devices industry artificial intelligence deals of Q2 2021 tracked by GlobalData were:
1) B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus’ $255m venture financing of InSilico Medicine
2) The $165m venture financing of PathAI by 8VC , Adage Capital Partners, Biospring Partners, Bristol-Myers Squibb, D1 Capital Partners, General Atlantic, General Catalyst Partners, Kaiser Permanente Ventures, KdT Ventures, LabCorp Venture Fund, Merck Global Health Innovation Fund, Polaris Partners, Refactor Capital and Tiger Global Management
3) AME Cloud Ventures, Ardea Partners, Aspect Ventures, AXA Venture Partners, Canvas Ventures, Centene, General Atlantic, NGP Capital and Workday Ventures’ $110m venture financing of Vida Health
4) The $100m venture financing deal with Caresyntax by Arno Capital, Intel Capital, IPF Management, Lauxera Capital Partners, Optum Ventures, PFM Health Sciences, Relyens, Rezayat Investments, Surgical.ai and Vesalius Biocapital III Partners
5) Brighton Park Capital’s venture financing with XSOLIS for $75m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.